Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Insmed (Nasdaq: INSM) reported third-quarter 2025 results and a business update on October 30, 2025. Total revenue was $142.3 million in Q3 2025, driven by ARIKAYCE $114.3M (+22% YoY) and BRINSUPRI $28.1M following FDA approval and U.S. launch. The company raised full-year ARIKAYCE guidance to $420M–$430M (15%–18% YoY growth).
R&D and SG&A each were $186.4M in Q3, and Insmed reported a net loss of $370.0M (−$1.75/share). Cash and marketable securities totaled about $1.7B as of Sept 30, 2025. Key clinical catalysts are expected through 2026 across ARIKAYCE, brensocatib, and TPIP programs.
Insmed (Nasdaq: INSM) ranked No. 1 on Science's 2025 Top Biopharma Employers list, marking a record fifth consecutive year at the top, announced Oct. 23, 2025. The ranking is based on about 5,500 survey responses, primarily from North America (66%), Europe (20%), and Asia/Pacific Rim (9%). The company linked the recognition to a people-first culture and cited recent clinical successes and regulatory milestones as drivers of growth. Insmed highlighted strengths in corporate image, financial prowess, leadership, work culture, and intellectual challenge. More details and rankings are available on the publisher's feature and Insmed's culture page.
Insmed (Nasdaq: INSM) announced that the EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on BRINSUPRI (brensocatib 25 mg) on October 17, 2025, recommending approval for treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older with two or more exacerbations in the prior 12 months.
BRINSUPRI was reviewed under the CHMP's accelerated assessment and had prior PRIME designation; the opinion is based on Phase 3 ASPEN and Phase 2 WILLOW data published in the New England Journal of Medicine. The European Commission will issue a final decision in the coming months.
Insmed (Nasdaq: INSM) will present six abstracts from the Phase 3 ASPEN trial of BRINSUPRI (brensocatib) at CHEST 2025 in Chicago, Oct 19–22, 2025. Presentations include prespecified and post‑hoc subgroup analyses, a late‑breaking high‑resolution CT substudy on structural lung changes, NSP (neutrophil serine protease) suppression data, and analyses of efficacy, symptom burden, and biomarker effects in patients with non‑cystic fibrosis bronchiectasis (NCFB).
Sessions cover COPD comorbidity, Asian population outcomes, BEST symptom assessments during and outside exacerbations, and multiple poster and oral presentations led by named investigators across Oct 20–22, 2025.
Insmed (Nasdaq: INSM) will release its third-quarter 2025 financial results on Thursday, October 30, 2025. Management will host a conference call for investors at 8:00 a.m. ET the same day to discuss results and provide a business update.
Investors may dial (888) 210-2654 (U.S.) or (646) 960-0278 (international) using access code 7862189, or listen via live webcast at www.insmed.com. A replay will be available about one hour after the call through November 6, 2025 by dialing (800) 770-2030 (U.S.) or (609) 800-9909 (international) with access code 7862189. The webcast will be archived for 90 days under the Investor Relations section of the company website.
Insmed (NASDAQ:INSM) will present seven abstracts from its late-stage portfolio at the European Respiratory Society (ERS) 2025 Congress from September 27 to October 1, 2025, in Amsterdam.
A key highlight includes data from the Phase 2b TPIP trial in pulmonary arterial hypertension patients, which will be featured in the prestigious ALERT session for late-breaking clinical data. Additionally, the company will present three prespecified subgroup analyses from the Phase 3 ASPEN trial evaluating brensocatib, including Japanese patient data, and Health Outcomes Research from the THIN database focusing on non-cystic fibrosis bronchiectasis (NCFB) patients in France and the UK.
The presentations will take place across multiple sessions, including oral presentations and poster sessions, showcasing various aspects of their clinical research and patient outcomes.
Insmed (Nasdaq: INSM) has granted inducement awards to 115 new employees under its 2025 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The grants, approved on August 29, 2025, include 70,742 restricted stock units and options to purchase 8,420 shares at $136.10 per share.
The restricted stock units feature a four-year vesting schedule with 25% vesting annually. The stock options have a 10-year term with 25% vesting after the first year and 12.5% vesting semi-annually for the following three years, subject to continued employment.
Insmed (Nasdaq: INSM), a global biopharmaceutical company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Wells Fargo 2025 Healthcare Conference in Boston on September 5 at 8:00 a.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9 at 4:50 p.m. ET.
Both presentations will be available via webcast through Insmed's investor relations website and will remain accessible for 30 days after the events.
Insmed (Nasdaq: INSM) has achieved a historic milestone with the FDA approval of BRINSUPRI™ (brensocatib), the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older. This first-in-class oral DPP1 inhibitor targets neutrophilic inflammation, a root cause of bronchiectasis exacerbations.
The approval is supported by Phase 3 ASPEN and Phase 2 WILLOW studies, showing significant clinical benefits: BRINSUPRI demonstrated a 21.1% reduction in annual exacerbation rates at 10mg and 19.4% at 25mg compared to placebo. The drug is now available in the U.S. through specialty pharmacies, addressing a market of approximately 500,000 diagnosed patients.
Insmed (Nasdaq: INSM) reported strong Q2 2025 financial results, with ARIKAYCE revenue reaching $107.4 million, up 19% year-over-year. The company maintained its 2025 ARIKAYCE revenue guidance of $405-425 million.
Key developments include: pending FDA approval for brensocatib in bronchiectasis (PDUFA date: August 12, 2025), positive Phase 2b results for TPIP in PAH, and Phase 3 studies planned for PH-ILD and PAH. The company reported a Q2 net loss of $321.7 million ($1.70 per share) and holds a strong cash position of $1.9 billion following a successful public offering that raised $823.1 million.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
